table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 mild to moderate
COVID-19 mild to moderate
Immunosuppressants drugs
anakinra CORIMUNO-ANA-1
janus kinase (JAK) inhibitor
tofacitinib Murugesan
lenzilumab LIVE-AIR ...

0 studies excluded by filtering options 1

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons